HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that it has received a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. The expanded capabilities are designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor.
The patent strengthens HeartBeam’s intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company said the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications and device hardware.
HeartBeam’s platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025 (1).
The new patent represents a significant step forward in cardiac monitoring, potentially allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. By integrating acoustic sensing, the device can act as a digital stethoscope, capturing heart sounds that may indicate valve abnormalities. Thoracic impedance measurement can detect fluid buildup in the chest, a key indicator of worsening heart failure. These additions could transform how patients with chronic cardiac conditions are monitored, enabling earlier intervention and reducing hospitalizations.
The implications for patients, healthcare providers, and the industry are substantial. For patients with heart failure or structural heart disease, the ability to self-monitor at home with a simple, non-invasive device could lead to better outcomes and improved quality of life. Healthcare systems may benefit from reduced costs associated with emergency visits and hospital stays. The patent also strengthens HeartBeam’s competitive position in the rapidly growing remote cardiac monitoring market, where multi-modal sensing is becoming increasingly important.
HeartBeam holds over 20 issued patents related to technology enablement. The full press release is available at https://ibn.fm/jgVf0. For more information about the company, visit its newsroom at https://ibn.fm/BEAT. Cleared indications for use are available at https://www.heartbeam.com/indications.
(1) The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use for details on the intended use of its technology.
